ANGO logo

AngioDynamics Inc. (ANGO)

$11.78

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ANGO

Market cap

$495401421

EPS

-0.79

P/E ratio

--

Price to sales

1.49

Dividend yield

--

Beta

0.29476

Price on ANGO

Previous close

$11.87

Today's open

$11.96

Day's range

$11.62 - $12.01

52 week range

$9.39 - $16.29

Profile about ANGO

CEO

Eric Honroth

Employees

632

Headquarters

Latham, NY

Exchange

Nasdaq Global Select

Shares outstanding

42054450

Issue type

Common Stock

ANGO industries and sectors

Healthcare

Medical Equipment & Supplies

News on ANGO

Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

ANGO's strong NanoKnife sales, expanding Med Tech portfolio and solid fiscal Q1 results support growth prospects, despite tariff and inflation pressures.

news source

Zacks Investment Research • Nov 13, 2026

news preview

AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the grant of inducement awards to Eric Honroth in connection with his appointment as Chief Executive Officer of the Company effective as of November 2, 2026. On November 2, 2026 (the “Grant Date”), as an inducement.

news source

Business Wire • Nov 6, 2026

news preview

AngioDynamics to Participate in Upcoming Investor Conferences

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management is scheduled to participate in the following upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 9, 2026, from 8:00-8:35 AM ET Canaccord Genuity's MedT.

news source

Business Wire • Oct 29, 2026

news preview

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in.

news source

Business Wire • Oct 21, 2026

news preview

AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist

AngioDynamics, Inc. remains a volatile small-cap med-tech, with promising growth drivers but inconsistent execution and margin trajectory. ANGO's AlphaVac, Auryon, and NanoKnife are gaining traction, yet face entrenched competitors and unpredictable clinician adoption, especially for NanoKnife. Recent results showed strong Med Tech growth and margin improvement, but higher-than-expected operating expenses and NanoKnife volatility spooked investors.

news source

Seeking Alpha • Oct 15, 2026

news preview

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec.

news source

Business Wire • Oct 14, 2026

news preview

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.

news source

Zacks Investment Research • Oct 9, 2026

news preview

Why AngioDynamics Crashed Today

AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.

news source

The Motley Fool • Oct 8, 2026

news preview

AngioDynamics Q1 Earnings Call Highlights

AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announced that Eric Honroth will become president and chief executive officer effective Nov. 2.

news source

MarketBeat • Oct 8, 2026

news preview

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript

news source

Seeking Alpha • Oct 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in AngioDynamics Inc.

Open an M1 investment account to buy and sell AngioDynamics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ANGO on M1